Spartalizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | PDCD1, CD279 |
| Clinical data | |
| Other names | PDR001 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Spartalizumab (INN;[1] development code PDR001) is a monoclonal antibody that is being investigated for melanoma.
This drug is being developed by Novartis. As of 2018[update], spartalizumab is undergoing Phase III trials.
References
- ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |